[1. Yamaguchi H, Chang SS, Hsu JL, Hung MC. Signaling cross-talk in the resistance to HER family receptor targeted therapy. Oncogene 2014; 33: 1073-81.10.1038/onc.2013.74387441923542173]Search in Google Scholar
[2. Sen M, Joyce S, Panahandeh M, Li C, Thomas SM, Maxwell J, Wang L, et al. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. Clin Cancer Res 2012; 18: 4986-96.10.1158/1078-0432.CCR-12-0792344570622825581]Search in Google Scholar
[3. Nahta R, Esteva FJ. Trastuzumab: triumphs and tribulations. Oncogene 2007; 26: 3637-43.10.1038/sj.onc.121037917530017]Search in Google Scholar
[4. Morgillo F, Bareschino MA, Bianco R, Tortora G, Ciardiello F. Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. Differentiation 2007; 75: 788-99.10.1111/j.1432-0436.2007.00200.x17608727]Search in Google Scholar
[5. Calabrò F, Sternberg CN. Metastatic bladder cancer: anything new? Curr Opin Support Palliat Care 2012; 6: 304-9.]Search in Google Scholar
[6. Siefker-Radtke A. Bladder cancer: can we move beyond chemotherapy? Curr Oncol Rep 2010; 12: 278-83.]Search in Google Scholar
[7. Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, et al. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 2009; 15: 5060-7210.1158/1078-0432.CCR-08-2245593862419671845]Search in Google Scholar
[8. Kassouf W, Dinney CP, Brown G, McConkey DJ, Diehl AJ, Bar-Eli M, et al. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. Cancer Res 2005; 65: 10524-35.10.1158/0008-5472.CAN-05-153616288045]Search in Google Scholar
[9. Goldenberg DM, and Sharkey RM. Using antibodies to target cancer therapeutics Expert Opin Biol Ther 2012; 12: 1173-90.]Search in Google Scholar
[10. Thomadsen B, Erwin W, Mourtada F. The physics and radiobiology of targeted radionuclide therapy. In: Speer TW, ed. Targeted radionuclide therapy. Lippincott Williams & Wilkins, Philadelphia; 2011, Chapter 6, p. 71-87. ISBN 978-0-7817-9693-4.]Search in Google Scholar
[11. Löfblom J, Feldwisch J, Tolmachev V, Carlsson J, Ståhl S, Frejd FY. Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett 2010; 584: 2670-80.10.1016/j.febslet.2010.04.01420388508]Search in Google Scholar
[12. Carlsson J, Stigbrand T, Adams GP. Introduction to radionuclide therapy. In: Stigbrand T, Adams G, Carlsson J, editors. Targeted radionuclide tumor therapy, biological aspects. Springer Verlag. Springer Science+Business Media France; 2008, Chapter 1, p. 1-11. ISBN 978-1-4020-8695-3.10.1007/978-1-4020-8696-0_1]Search in Google Scholar
[13. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-37.10.1038/3505207311252954]Search in Google Scholar
[14. Avraham R, Yarden Y. Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat Rev Mol Cell Biol 2011; 12: 104-17.10.1038/nrm304821252999]Search in Google Scholar
[15. Bublil EM, Yarden Y. The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol 2007; 19: 124-34.10.1016/j.ceb.2007.02.00817314037]Search in Google Scholar
[16. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006; 7: 505-16.10.1038/nrm196216829981]Search in Google Scholar
[17. Mosesson Y, Yarden Y. Oncogenic growth factor receptors: implications for signal transduction therapy. Semin Cancer Biol 2004; 14: 262-70.10.1016/j.semcancer.2004.04.00515219619]Search in Google Scholar
[18. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19: 6550-65.10.1038/sj.onc.120408211426640]Search in Google Scholar
[19. Parkin DM. The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl 2008; 218: 12-20.10.1080/0300888080228503219054893]Search in Google Scholar
[20. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.10.1002/ijc.2551621351269]Search in Google Scholar
[21. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49: 1374-403.10.1016/j.ejca.2012.12.02723485231]Search in Google Scholar
[22. Gardmark T, Wester K, DeLa Torre M, Carlsson J, Malmström PU. Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. Brit J Urol (BJU) 2005; 95: 982-86.10.1111/j.1464-410X.2005.05452.x15839918]Search in Google Scholar
[23. Wester K, Sjostrom A, de la Torre M, Carlsson J, Malmstrom PU. HER-2--a possible target for therapy of metastatic urinary bladder carcinoma. Acta Oncol 2002; 41: 282-88.10.1080/0284186026008883612195748]Search in Google Scholar
[24. Wei Q, Chen L, Sheng L, Nordgren H, Wester K, Carlsson J: EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int J Oncol 2007; 31: 493-9.]Search in Google Scholar
[25. Bilous M, Dowsett M, Hanna W, Isola J, Lebeau A, Moreno A, et al. Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol 2003; 16: 173-182.10.1097/01.MP.0000052102.90815.8212591971]Search in Google Scholar
[26. Fleischmann A, Rotzer D, Seiler R, Studer UE, Thalmann GN. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur Urol 2011; 60: 350-7.10.1016/j.eururo.2011.05.035]Search in Google Scholar
[27. Caner V, Turk NS, Duzcan F, Tufan NL, Kelten EC, Zencir S, et al. No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas. Pathol Oncol Res 2008; 14: 261-6.10.1007/s12253-008-9027-y]Search in Google Scholar
[28. Hauser-Kronberger C, Peham K, Grall J, Rausch W, Hutarew G, Dietze O. Novel approach of human epidermal growth factor receptor 2 detection in noninvasive and invasive transitional cell carcinoma of the bladder. J Urol 2006; 175(3 Pt 1): 875-80.10.1016/S0022-5347(05)00411-8]Search in Google Scholar
[29. Latif Z, Watters AD, Dunn I, Grigor K, Underwood MA, Bartlett JM. HER2/ neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur J Cancer 2004; 40: 56-63.]Search in Google Scholar
[30. Sanchez KM, Sweeney CJ, Mass R, Koch MO, Eckert GJ, Geary WA, et al. Evaluation of HER-2/neu expression in prostatic adenocarcinoma: a requested for a standardized, organ specific methodology. Cancer 2002; 95: 1650-5.10.1002/cncr.1083912365012]Search in Google Scholar
[31. Baum RP, Prasad V, Muller D, Schuchardt C, Orlova A, Wennborg A, et al. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled Affibody molecules. J Nucl Med 2010; 51: 89-97.10.2967/jnumed.109.07323920484419]Search in Google Scholar
[32. Tolmachev V. Imaging of HER-2 overexpression in tumors for guiding therapy. Curr Pharm Des 2008; 14: 2999-3019.10.2174/13816120878640429018991715]Search in Google Scholar
[33. Heskamp S, van Laarhoven HW, Oyen WJ, van der Graaf WT, Boerman OC. Tumor-receptor imaging in breast cancer: a tool for patient selection and response monitoring. Curr Mol Med 2013; 13: 1506-22.10.2174/156652401366613111112063824206139]Search in Google Scholar
[34. Fox JJ, Schöder H, Larson SM. Molecular imaging of prostate cancer. Curr Opin Urol 2012; 22: 320-7.10.1097/MOU.0b013e32835483d5437334922617062]Search in Google Scholar
[35. Perik PJ, Lub-De Hooge MN, Gietema JA, van der Graaf WT, de Korte MA, Jonkman S et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2006; 24: 2276-82.10.1200/JCO.2005.03.844816710024]Search in Google Scholar
[36. Chen PC, Yu HJ, Chang YH, Pan CC. Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression. J Clin Pathol 2013; 66: 113-9.10.1136/jclinpath-2012-20094423087329]Search in Google Scholar
[37. Bolenz C, Shariat SF, Karakiewicz PI, Ashfaq R, Ho R, Sagalowsky AI, et al. Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. BJU Int. 2010; 106: 1216-22.10.1111/j.1464-410X.2009.09190.x20089105]Search in Google Scholar
[38. Bolenz C, Lotan Y. Translational research in bladder cancer: from molecular pathogenesis to useful tissue biomarkers. Cancer Biol Ther 2010; 10: 407-15.10.4161/cbt.10.5.1302220686360]Search in Google Scholar
[39. Kolla SB, Seth A, Singh MK, Gupta NP, Hemal AK, Dogra PN, et al Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy. Int Urol Nephrol 2008; 40: 321-7.10.1007/s11255-007-9283-x17899426]Search in Google Scholar
[40. Black PC, Dinney CP. Growth factors and receptors as prognostic markers in urothelial carcinoma. Curr Urol Rep 2008; 9: 55-61.10.1007/s11934-008-0011-618366975]Search in Google Scholar
[41. Krüger S, Weitsch G, Büttner H, Matthiensen A, Böhmer T, Marquardt T, et al. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int J Cancer 2002; 102: 514-8.10.1002/ijc.1073112432555]Search in Google Scholar
[42. Jimenez RE, Hussain M, Bianco FJ Jr, Valshampayan U, Tabazcka P, Sakr WA, et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 2001; 7: 2440-7.]Search in Google Scholar
[43. Carlsson J. Potential for clinical radionuclide based imaging and therapy of common cancers expressing EGFR-family receptors. Tumor Biol 2012; 33: 653-9.10.1007/s13277-011-0307-x22228543]Search in Google Scholar
[44. Chaux A, Cohen JS, Schultz L, Albadine R, Jadallah S, Murphy KM, et al. High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: a study using formalin-fixed, paraffin-embedded archival tissues. Hum Pathol 2012; 43: 1590-5.10.1016/j.humpath.2011.11.016350567322406363]Search in Google Scholar
[45. Carlsson J. EGFR-family expression and implications for targeted radionuclide therapy. In: Stigbrand T, Adams G, Carlsson J, editors. Targeted radionuclide tumor therapy, biological aspects. Springer Verlag. Springer Science+Business Media France; 2008, Chapter 3, p. 25-58. ISBN 978-1-4020-8695-3.10.1007/978-1-4020-8696-0_3]Search in Google Scholar
[46. Velikyan I, Sundin A, Eriksson B, Lundqvist H, Sörensen J, Bergström M, et al. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide mass. Nucl Med Biol 2010; 37: 265-75. 10.1016/j.nucmedbio.2009.11.00820346866]Search in Google Scholar
[47 . Tolmachev V, Tran TA, Rosik D, Sjoberg A, Abrahmsen L, Orlova A. Tumor targeting using affibody molecules: interplay of affinity, target expression level, and binding site composition. J Nucl Med 2012; 53: 953-60. 10.2967/jnumed.111.10152722586147]Search in Google Scholar
[48 . Tolmachev V, Wallberg H, Sandstrom M, Hansson M, Wennborg A, Orlova A. Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels. Eur J Nucl Med Mol Imaging 2011; 38: 531-39.10.1007/s00259-010-1646-3]Search in Google Scholar
[49. Damjanov I, Mildner B, Knowles BB. Immunohistochemical localization of the epidermal growth factor receptor in normal human tissues. Lab Invest 1986; 55: 588-92. ]Search in Google Scholar
[50. Gusterson B, Cowley G, Smith JA, Ozanne B. Cellular localisation of human epidermal growth factor receptor. Cell Biol Int Rep 1984; 8: 649-58.10.1016/0309-1651(84)90045-6]Search in Google Scholar
[51. Skagias L, Politi E, Karameris A, Sambaziotis D, Archondakis A, Vasou O, et al. Prognostic impact of HER2/neu protein in urothelial bladder cancer. Survival analysis of 80 cases and an overview of almost 20 years’ research. J BUON 2009; 14: 457-62.]Search in Google Scholar
[52. Naik DS, Sharma S, Ray A, Hedau S. Epidermal growth factor receptor expression in urinary bladder cancer. Indian J Urol 2011; 27: 208-14.10.4103/0970-1591.82839314283121814311]Search in Google Scholar
[53. Natali PG, Nicotra MR, Bigotti A, Venturo I, Slamon DJ, Fendly BM, et al. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer 1990; 45: 457-61.10.1002/ijc.29104503141968437]Search in Google Scholar
[54. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu protooncogene in normal human adult and fetal tissues. Oncogene 1990; 5: 953-62.]Search in Google Scholar
[55. Govindan SV, Goldenberg DM. Designing immunoconjugates for cancer therapy. Expert Opin Biol Ther 2012; 12: 873-90.10.1517/14712598.2012.68515322679911]Search in Google Scholar
[56. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783-91.10.1056/NEJMoa1209124512525023020162]Search in Google Scholar
[57. Witzig TE, Fishkin P, Gordon LI, Gregory SA, Jacobs S, Macklis R, et al. Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report. Leuk Lymphoma 2011; 52: 1188-99.10.3109/10428194.2011.57039621599576]Search in Google Scholar
[58. Press OW. Radiolabeled antibody therapy of B-cell lymphomas. Semin Oncol 1999; 26(5 Suppl 14): 58-65.]Search in Google Scholar
[59. Kam BL, Teunissen JJ, Krenning EP, de Herder WW, Khan S, van Vliet EI, et al. Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2012; 39(Suppl 1): S103-12.10.1007/s00259-011-2039-y330406522388631]Search in Google Scholar
[60. Sandström M, Garske U, Granberg D, Sundin A, Lundqvist H. Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate. Eur J Nucl Med Mol Imaging 2010; 37: 212-25.10.1007/s00259-009-1216-819727718]Search in Google Scholar
[61. Williams SP. Tissue distribution studies of protein therapeutics using molecular probes: molecular imaging. AAPS J 2012; 14: 389-99.10.1208/s12248-012-9348-3338580922467336]Search in Google Scholar
[62. Matthews PM, Rabiner EA, Passchier J, Gunn RN. Positron emission tomography molecular imaging for drug development. Br J Clin Pharmacol 2012; 73: 175-86.10.1111/j.1365-2125.2011.04085.x326957621838787]Search in Google Scholar
[63. Ståhl S, Friedman M, Carlsson J, Tolmachev V, Frejd F. Affibody molecules for targeted radionuclide therapy. In: Speer TW, editor. Targeted radionuclide therapy. Lippincott Williams & Wilkins; 2011. Chapter 4, p. 49-58.]Search in Google Scholar
[64. Gomes CM, Abrunhosa AJ, Ramos P, Pauwels EK. Molecular imaging with SPECT as a tool for drug development. Adv Drug Deliv Rev 2011; 63: 547-54.10.1016/j.addr.2010.09.01520933557]Search in Google Scholar
[65. Fondell A, Edwards K, Ickenstein LM, Sjöberg S, Carlsson J, Gedda L. Nuclisome: A novel concept for radionuclide therapy using targeting liposomes. Eur J Nucl Med Mol Imaging 2010; 37: 114-23.10.1007/s00259-009-1225-719662408]Search in Google Scholar
[66. Stigbrand T, Carlsson J, Adams GP. Developmental trends in targeted radionuclide therapy - biological aspects. In: Stigbrand T, Adams G, Carlsson J, editors. Targeted radionuclide tumor therapy, biological aspects. Springer verlag. Springer Science+Business Media France; 2008, Chapter 21, p. 387-97. ISBN 978-1-4020-8695-3.10.1007/978-1-4020-8696-0_21]Search in Google Scholar
[67. Persson M, Gedda L, Lundqvist H, Tolmachev V, Nordgren H, Malmstrom PU et al. [177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts. Cancer Res 2007; 67: 326-31. 10.1158/0008-5472.CAN-06-236317210714]Search in Google Scholar